{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T12:02:23Z","timestamp":1717761743651},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2013,8,31]],"date-time":"2013-08-31T00:00:00Z","timestamp":1377907200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1007\/s40273-013-0083-0","type":"journal-article","created":{"date-parts":[[2013,8,30]],"date-time":"2013-08-30T11:18:15Z","timestamp":1377861495000},"page":"841-852","source":"Crossref","is-referenced-by-count":15,"title":["Ruxolitinib for the Treatment of Myelofibrosis: A NICE Single Technology Appraisal"],"prefix":"10.1007","volume":"31","author":[{"given":"Ros","family":"Wade","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micah","family":"Rose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aileen Rae","family":"Neilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Stirk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rocio","family":"Rodriguez-Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Bowen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawn","family":"Craig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nerys","family":"Woolacott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,8,31]]},"reference":[{"key":"83_CR1","unstructured":"National Institute for Health and Clinical Excellence. Guide to the single technology appraisal (STA) process. London: NICE; 2006."},{"key":"83_CR2","unstructured":"Craig D, et al. Ruxolitinib for the treatment of myelofibrosis. Southampton: Health Technology Assessment Programme; 2012."},{"key":"83_CR3","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40273-012-0018-1","volume":"31","author":"D Craig","year":"2013","unstructured":"Craig D, et al. Retigabine for the adjunctive treatment of adults with partial-onset seizures in epilepsy with and without secondary generalization. A NICE Single Technology Appraisal. Pharmacoeconomics. 2013;31:101\u201310.","journal-title":"Pharmacoeconomics"},{"key":"83_CR4","doi-asserted-by":"crossref","unstructured":"Kearns B, et al. Cabazitaxel for the second-line treatment of metastatic hormone refractory prostate cancer. A NICE Single Technology Appraisal. Pharmacoeconomics. 2013;31:479\u201388.","DOI":"10.1007\/s40273-013-0050-9"},{"key":"83_CR5","doi-asserted-by":"crossref","unstructured":"Tosh J, et al. Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs. A NICE Single Technology Appraisal. Pharmacoeconomics. 2013;31:653\u201361.","DOI":"10.1007\/s40273-013-0052-7"},{"key":"83_CR6","doi-asserted-by":"crossref","unstructured":"Armstrong N, et al. Golimumab for the treatment of ankylosing spondylitis. A NICE Single Technology Appraisal. Pharmacoeconomics. 2013;31:415\u201325.","DOI":"10.1007\/s40273-013-0049-2"},{"key":"83_CR7","doi-asserted-by":"crossref","unstructured":"Greenhalgh J, et al. Rituximab for the firstline maintenance treatment of follicular non-Hodgkin\u2019s lymphoma. A NICE Single Technology Appraisal. Pharmacoeconomics. 2013;31:403\u201313.","DOI":"10.1007\/s40273-013-0043-8"},{"issue":"4","key":"83_CR8","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s40273-013-0036-7","volume":"31","author":"EL Simpson","year":"2013","unstructured":"Simpson EL, et al. Bivalirudin for the treatment of ST-segment elevation myocardial infarction. A NICE Single Technology Appraisal. Pharmacoeconomics. 2013;31(4):269\u201375.","journal-title":"Pharmacoeconomics"},{"key":"83_CR9","doi-asserted-by":"crossref","unstructured":"Rafia R, et al. Trabectedin for the treatment of advanced metastatic soft tissue sarcoma. A NICE Single Technology Appraisal. Pharmacoeconomics. 2013;31:471\u20138.","DOI":"10.1007\/s40273-013-0044-7"},{"issue":"3","key":"83_CR10","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s40273-013-0023-z","volume":"31","author":"E Spackman","year":"2013","unstructured":"Spackman E, et al. Trastuzumab for the treatment of HER2 positive metastatic gastric cancer. A NICE Single Technology Appraisal. Pharmacoeconomics. 2013;31(3):185\u201394.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"83_CR11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40273-012-0006-5","volume":"31","author":"M Kilonzo","year":"2013","unstructured":"Kilonzo M, Hislop J, Elders A. Pazopanib for the first-line treatment of patients with advanced and\/or metastatic renal cell carcinoma. A NICE Single Technology Appraisal. Pharmacoeconomics. 2013;31(1):15\u201324.","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"83_CR12","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2165\/11535680-000000000-00000","volume":"28","author":"M Sculpher","year":"2010","unstructured":"Sculpher M. Single technology appraisal at the UK National Institute for Health and Clinical Excellence: a source of evidence and analysis for decision making internationally. Pharmacoeconomics. 2010;28(5):347\u20139.","journal-title":"Pharmacoeconomics"},{"issue":"12","key":"83_CR13","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.2165\/11591600-000000000-00000","volume":"29","author":"R Dickson","year":"2011","unstructured":"Dickson R, et al. Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy. A NICE Single Technology Appraisal. Pharmacoeconomics. 2011;29(12):1051\u201362.","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"83_CR14","doi-asserted-by":"crossref","first-page":"951","DOI":"10.2165\/11589310-000000000-00000","volume":"29","author":"G Scotland","year":"2011","unstructured":"Scotland G, et al. Denosumab for the prevention of osteoporotic fractures in post-menopausal women. A NICE Single Technology Appraisal. Pharmacoeconomics. 2011;29(11):951\u201361.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"83_CR15","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2165\/11535770-000000000-00000","volume":"29","author":"M Stevenson","year":"2011","unstructured":"Stevenson M, Pandor A. Febuxostat for the management of hyperuricaemia in patients with gout. A NICE Single Technology Appraisal. Pharmacoeconomics. 2011;29(2):133\u201340.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"83_CR16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/11594280-000000000-00000","volume":"30","author":"C McKenna","year":"2012","unstructured":"McKenna C, et al. Dronedarone for the treatment of atrial fibrillation. A NICE Single Technology Appraisal. Pharmacoeconomics. 2012;30(1):35\u201346.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"83_CR17","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2165\/11591590-000000000-00000","volume":"30","author":"M Holmes","year":"2012","unstructured":"Holmes M, Carroll C, Papaioannou D. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip or knee surgery. A NICE Single Technology Appraisal. Pharmacoeconomics. 2012;30(2):137\u201346.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"83_CR18","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2165\/11595920-000000000-00000","volume":"30","author":"HQ Yang","year":"2012","unstructured":"Yang HQ, et al. Golimumab for the treatment of psoriatic arthritis. A NICE Single Technology Appraisal. Pharmacoeconomics. 2012;30(4):257\u201370.","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"83_CR19","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2165\/11591550-000000000-00000","volume":"30","author":"D Boyers","year":"2012","unstructured":"Boyers D, et al. Eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura. A NICE Single Technology Appraisal. Pharmacoeconomics. 2012;30(6):483\u201395.","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"83_CR20","doi-asserted-by":"crossref","first-page":"991","DOI":"10.2165\/11597160-000000000-00000","volume":"30","author":"J Burch","year":"2012","unstructured":"Burch J, et al. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6\u201311\u00a0years. A NICE Single Technology Appraisal. Pharmacoeconomics. 2012;30(11):991\u20131004.","journal-title":"Pharmacoeconomics"},{"issue":"12","key":"83_CR21","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.2165\/11597210-000000000-00000","volume":"30","author":"S Whyte","year":"2012","unstructured":"Whyte S, Pandor A, Stevenson M. Bevacizumab for metastatic colorectal cancer. A NICE Single Technology Appraisal. Pharmacoeconomics. 2012;30(12):1119\u201332.","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"83_CR22","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2165\/11532220-000000000-00000","volume":"28","author":"A Bagust","year":"2010","unstructured":"Bagust A, et al. Cetuximab for recurrent and\/or metastatic squamous cell carcinoma of the head and neck\/A NICE Single Technology Appraisal. Pharmacoeconomics. 2010;28(6):439\u201348.","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"83_CR23","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2165\/11532160-000000000-00000","volume":"28","author":"M Rodgers","year":"2010","unstructured":"Rodgers M, et al. Alitretinoin for severe chronic hand eczema. A NICE Single Technology Appraisal. Pharmacoeconomics. 2010;28(5):351\u201362.","journal-title":"Pharmacoeconomics"},{"key":"83_CR24","unstructured":"National Institute for Health and Clinical Excellence. Myelofibrosis (splenomegaly, symptoms)\u2014ruxolitinib [ID510]. 2013 (cited 2013 February). http:\/\/guidance.nice.org.uk\/TA\/Wave0\/615 ."},{"issue":"6","key":"83_CR25","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3324\/haematol.2008.004234","volume":"94","author":"F Girodon","year":"2009","unstructured":"Girodon F, et al. Significant increase in the apparent incidence of essential thrombocythemia related to new WHO diagnostic criteria: a population-based study. Haematologica. 2009;94(6):865\u20139.","journal-title":"Haematologica"},{"issue":"4","key":"83_CR26","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/(SICI)1099-1069(199711)15:4<173::AID-HON610>3.0.CO;2-K","volume":"15","author":"RJ McNally","year":"1997","unstructured":"McNally RJ, et al. Age and sex distributions of hematological malignancies in the U.K. Hematol Oncol. 1997;15(4):173\u201389.","journal-title":"Hematol Oncol"},{"issue":"10","key":"83_CR27","first-page":"1400","volume":"91","author":"KJ Phekoo","year":"2006","unstructured":"Phekoo KJ, et al. The incidence and outcome of myeloid malignancies in 2,112 adult patients in southeast England. Haematologica. 2006;91(10):1400\u20134.","journal-title":"Haematologica"},{"key":"83_CR28","unstructured":"Orphanet. Prevalence of rare diseases: bibliographic data, Paris; 2012. p. 30."},{"key":"83_CR29","unstructured":"European Medicines Agency (EMA) and Committee for Orphan Medicinal Products. In: Public summary of opinion on orphan designation. (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate for the treatment of myelofibrosis secondary to polycythaemia vera or essential thrombocythaemia. London: European Medicines Agency; 2011. p. 5."},{"key":"83_CR30","unstructured":"Novartis. Single Technology Appraisal (STA): Ruxolitinib (Jakavi) for the treatment of primary myelofibrosis, post-polycythaemia vera myelofibrosis and post-essential thrombocythaemia myelofibrosis. Manufacturer\u2019s submission. 2012. p. 294."},{"issue":"9","key":"83_CR31","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","volume":"366","author":"C Harrison","year":"2012","unstructured":"Harrison C, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787\u201398.","journal-title":"N Engl J Med"},{"issue":"9","key":"83_CR32","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799\u2013807.","journal-title":"N Engl J Med"},{"key":"83_CR33","unstructured":"National Institute for Health and Clinical Excellence (NICE). Final scope for the proposed appraisal of ruxolitinib for the treatment of myelofibrosis. London: National Institute for Health and Clinical Excellence; 2012."},{"key":"83_CR34","unstructured":"Committee for Medicinal Products for Human Use (CHMP). CHMP assessment report: Jakavi Ruxolitinib. EMA\/465846\/2012. 2012 (cited 2012). http:\/\/www.emea.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002464\/WC500133226.pdf ."},{"issue":"12","key":"83_CR35","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","volume":"363","author":"S Verstovsek","year":"2010","unstructured":"Verstovsek S, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363(12):1117\u201327.","journal-title":"N Engl J Med"},{"key":"83_CR36","doi-asserted-by":"crossref","unstructured":"Harrison CN, et al. Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) or post-essential thrombocythemia-myelofibrosis (PET-MF). J Clin Oncol. 2011;29(18 Suppl. 1):LBA6501.","DOI":"10.1200\/jco.2011.29.18_suppl.lba6501"},{"key":"83_CR37","doi-asserted-by":"crossref","unstructured":"Verstovsek S, et al. Long-term outcome of Ruxolitinib treatment in patients with Myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT-I. Abstract Number 800, in 54th ASH Annual Meeting, Atlanta, 2012.","DOI":"10.1182\/blood.V120.21.800.800"},{"key":"83_CR38","doi-asserted-by":"crossref","unstructured":"Cervantes F., et al. Long-term safety, efficacy, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF). Abstract Number 801, in 54th ASH Annual Meeting, Atlanta, 2012.","DOI":"10.1182\/blood.V120.21.801.801"},{"key":"83_CR39","doi-asserted-by":"crossref","unstructured":"Verstovsek S, et al. A phase I\/II study of INCB018424, an oral, selective JAK inhibitor, in patients with primary myelofibrosis (PMF) and post polycythemia vera\/essential thrombocythemia myelofibrosis (Post-PV\/ET MF). J Clin Oncol. 2008;26(15):7004.","DOI":"10.1200\/jco.2008.26.15_suppl.7004"},{"issue":"13","key":"83_CR40","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","volume":"113","author":"F Cervantes","year":"2009","unstructured":"Cervantes F, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113(13):2895\u2013901.","journal-title":"Blood"},{"key":"83_CR41","unstructured":"National Institute for Health and Clinical Excellence (NICE). Eribulin for the treatment of advanced metastatic breast cancer (TA250). London: National Institute for Health and Clinical Excellence; 2012. p. 67."},{"key":"83_CR42","unstructured":"Roskell NS, et al. Using a condition-specific measure of patient-reported outcomes to derive utilities in myelofibrosis. In: ISPOR 17th annual international meeting, Washington, DC, 2012."},{"issue":"4","key":"83_CR43","doi-asserted-by":"crossref","first-page":"A224","DOI":"10.1016\/j.jval.2012.03.1212","volume":"15","author":"NS Roskell","year":"2012","unstructured":"Roskell NS, et al. Using a condition-specific measure of patient-reported outcomes to derive utilities in myelofibrosis. Value Health. 2012;15(4):A224\u20135.","journal-title":"Value Health"},{"key":"83_CR44","unstructured":"National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE; 2008. p. 76."},{"issue":"5","key":"83_CR45","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1182\/blood-2006-03-009746","volume":"108","author":"A Tefferi","year":"2006","unstructured":"Tefferi A, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood. 2006;108(5):1497\u2013503.","journal-title":"Blood"},{"key":"83_CR46","unstructured":"National Institute for Health and Care Excellence. Ruxolitinib for disease-related splenomegaly or symptoms in adults with myelofibrosis. Appraisal consultation document (ACD). 2013 (cited 2013 April 29). http:\/\/guidance.nice.org.uk\/TA\/Wave0\/615\/Consultation\/DraftGuidance ."},{"issue":"21","key":"83_CR47","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood.V118.21.1646.1646","volume":"118","author":"S Verstovsek","year":"2011","unstructured":"Verstovsek S, et al. The MD Anderson Cancer Center (MDACC) experience with ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis: long-term follow-up outcomes of 107 patients from a phase I\/II study. Blood. 2011;118(21):1646.","journal-title":"Blood"},{"issue":"12","key":"83_CR48","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.4065\/mcp.2011.0518","volume":"86","author":"A Tefferi","year":"2011","unstructured":"Tefferi A, Pardanani A. Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis. Mayo Clin Proc. 2011;86(12):1188\u201391.","journal-title":"Mayo Clin Proc"},{"key":"83_CR49","unstructured":"National Institute for Health and Care Excellence. Final appraisal determination: Ruxolitinib for disease-related splenomegaly or symptoms in adults with myelofibrosis. 2013 (cited 2013 April 29). http:\/\/www.nice.org.uk\/nicemedia\/live\/13687\/63722\/63722.pdf ."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-013-0083-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-013-0083-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-013-0083-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,2]],"date-time":"2020-08-02T21:25:14Z","timestamp":1596403514000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-013-0083-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,31]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["83"],"URL":"https:\/\/doi.org\/10.1007\/s40273-013-0083-0","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,31]]}}}